Harmony Biosciences Reports First Quarter 2022 Financial Results and Business Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall St futures rise on Mideast deal hopes; SpaceX debut in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Oil falls to near two-month lows as Trump calls off threatened strikes on Iran
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Axsome Therapeutics (AXSM) PT Raised to $380 at Jefferies
Harmony Biosciences (HRMY) Tops Q1 EPS by 20c
May 3, 2022 7:35 AM EDTHarmony Biosciences (NASDAQ: HRMY) reported Q1 EPS of $0.51, $0.20 better than the analyst estimate of $0.31. Revenue for the quarter came in at $85.3 million versus the consensus estimate of $89.61 million.
For earnings history and earnings-related data on Harmony Biosciences (HRMY) click here.
... More